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The mortality of tetanus treated symptomatically is estimated by
most observers at from 78 to 90 percent. A few authors have given
figures considerably lower than this, but these latter vary so greatly
from the average that it seems that the apparent reduction in mor-
tality must have been due to some unrecognized factor of selection
in the compilation of statistics.
TABLE 1
Percent
88.8
80.0
82.5
44.0
34.9
Fricker .
Posselt .
Faber .
Sorrnanni .
Kowalski .
MORTALITY OF TETANUS WITHOUT SERUM
(Hospital Statistics Collected by Permin)
Percent
82.5
86.0
89.3
88.0
85.7
78.0
Larrey .
Poland .
. American Civil War .
Richter .
Demme .
Rose .
A number of factors combine to influence the prognosis of the
individual case.
Tetanus is commonly divided into acute and chronic, according
to whether the interval between the injury and first appearance of
symptoms is eight to ten days or less, or more than ten days. This
arbitrary division affords a convenient method of estimating the
probable severity and mortality of the disease in a majority of
instances. Another criterion of the severity of tetanus is afforded
by the extent and rate of development of the symptoms after the
appearance of first stiffness of muscles, but this evidence is obvi-
ously not available at the onset of the disease.
In experimental tetanus produced by the injection of known
amounts of tetanus toxin, the incubation period, rapidity of develop-
ment of symptoms, elapsed time till death, and the mortality are
direct functions of the size of the dose. The site of injection also
IS important. In tetanus developing after wounds the problem is
* Received for publication June 27. 1914.
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368 ERNEST E. IRONS
Q10re complicated because the toxin is not received all at once, but
is absorbed gradually as fast as produced. The rate of production
depends in turn both on the amount of organisms introduced and on
whether they find favorable or unfavorable conditions of growth.
Conditions of growth may be favorable at once after the receipt
of the wound, as in a deep puncture, or extensive laceration, or
multiplication of the organisms may begin only after several days or
weeks have elapced.
In the majority of cases, the incubation period expresses with a
fair degree of accuracy the combination of these factors, although
not infrequently some one element such as conditions in the wound,
extent of surface injured, or amount of infection introduced may
TABLE 2
MORTALITY OF TETANUS IN DENMARK
Cases Treated Without Serum (Permin and Faber)
Incubation
10 days and less .
Over 10 days .
Unknown .
Totals .. , .
Lived
5
17
20
42
Died
89
40
28
157
Mortality,
Per Cent
94.7
70.2
58.3
78.9
Cases Treated with Serum (Permin)
Incubation Lived
10 days and less 25
Over 10 days 34
Unknown 21
Totals , ,. . 80
Mortality,
Died Per Cent
67 72.8
23 40.4
19 47.5
109 57.7
vary from the usual to such an extent that symptoms appear four
or five days after an injury, but develop slowly, so that the course
of the disease is relatively mild, or, on the other hand, the production
of tetanospasmin may be delayed for a number of days, and then
proceed rapidly so that a fulminant disease develops after a long
incubation period. If toxin is produced slowly in small amounts,
time is afforded for the production of antitoxin by the host, and
this probably has a part in the spontaneous recovery from the disease.
The evaluation of antitetanic serum in developed tetanus, a dis-
ease which presents so many variable factors influencing the prog-
nosis, is a matter of considerable difficulty, and many experienced
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TREATMENT OF TETANUS 369
clinicians have doubted whether the results obtained from its use
have been any better than those from symptomatic treatment. A
study of the statistics of mortality of many hospitals shows that too
often this skepticism has been well founded. Opposed to this pessi-
mistic view are the reports of a number of small groups of carefully
observed cases, such as those of Ashhurst and John in which the
evidence seems strong that antitoxin deserved large credit for the
recovery of some of the patients.
Permin- has collected statistics III Denmark of the mortality of
tetanus treated with and without serum and finds a mortality of
78.9 percent in 199 cases treated without serum, as compared with
a mortality of 57.7 percent in 189 cases receiving serum.
TABLE 3
CASES TREATED WITH SERUM
Incubation
11-15 days .
16 days and over .
Incubation known .
Incubation unknown .
Total cases .
Total
Cases
38
IS
21
17
24
13
131
47
22
69
200
25
225
Died
27
15
16
14
17
7
96
22
6
28
124
1;;
139
I Recovered
11
3
5
3
7
6
35
25
16
41
76
10
86
Mortality,
Per Cent
73.28
40.57
62.00
60.00
61.77
CASES WITHOUT SERUM
10 days and less .
Over 10 days .
Unknown .
Total .
12
4
5
21
1
2
o
85.7
The collection of the cases* of tetanus here analyzed was under-
taken with the object of ascertaining in the first place what results
1. Mitt. a. d. Grenzgeb. d. Med. 11. cu-; 1913, 27, p. 1
* All cases reported by anyone observer are included in so far as the completeness of
the data permit. The data of 80 cases were obtained by me directly from hospital records.
About 20 cases occurred in the private practice of physicians. The remainder were treated
in hospitals, for the most part large metropolitan-including Bellevue, Massachusetts General,
Boston City, Buffalo General, Philadelphia General, Royal Victoria and Cook County, Wesley,
Presbyterian and Michael Reese. To those who have kindly assisted in the collection
of cases my best thanks are extended. I am especially indebted to Drs. O. Berghausen,
Cincinnati; R. J. Carlisle, New York; Russell S. Fowler, Brooklyn; C. D. Fox, Philadelphia;
F. S. Graves, Boston; G. W. Green, Chicago; H. C. Marble; A. C. Morgan, Philadelphia;
John McCrae, Montreal; E. R. McGuire, Buffalo; J. J. Toland, Frankford, Pa.; Frank
Vander Bogert, Schenectady; H. B. Wadsworth, Washington, Ind., and to others who
supplied data of smaller numbers of cases.
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370 ERNEST E. IRONS
are being obtained in this country with antitetanic serum in the
treatment of tetanus (during the period 1907 to 1913), and in the
second place, whether the failures in some cases may not be ascribed
to the faulty and insufficient method of giving the serum. Statis-
tical studies of cases collected from the literature are necessarily
subject to error, and particularly in tetanus, such tabulations have
led to conclusions favorable to serum treatment to a degree unwar-
ranted by the actual facts.
With one or two possible exceptions, none of the cases in this
series have been reported, and all were obtained by personal cor-
respondence from hospital or private records. In all, this collection
includes 225 cases treated with antitetanic serum, and 21 cases which
received no serum.
Table 3 summarizes the mortality of the several classes of cases.
The mortality of all cases receiving serum is 61.77 percent; in
21 cases without serum the mortality is 85.7 percent. The number
of cases in this latter group is, of course, too small to establish a
mortality for tetanus, but it agrees with the generally accepted figures
of many writers on tetanus, 78 to 89 percent. It appears therefore
that the mortality of cases in this series is about 20 percent lower
in cases receiving serum than in those treated without serum. A
further analysis of the cases with respect to the size of the dose,
method of giving the serum, and duration of symptoms before the
serum was given suggests the reasons for failure in some cases.
DISTRIBUTION OF TOXIN IN TETANUS
In the average patient suffering from tetanus in whom symptoms
have just appeared the following conditions are present. Some of
the toxin has already reached the central nervous system, and trismus
or other evidence of tonic spasm suggests the diagnosis; another por-
tion of toxin is ascending centralward in the nerves supplying the
infected extremity; a still larger amount of toxin is present in the
blood and is being taken up and is traveling centralward along the
other nerves of the body. Some of these patients have already
received in' the peripheral and central nervous system a fatal dose of
toxin when they are first seen, and will die no matter what is done.
However, patients apparently hopeless, in whom convulsions have
already begun, may recover, and since at the present time there seems
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TREATMENT OF TETANUS 371
to be no criterion by which we may be sure that the fatal dose has
already reached the central nervous system, all cases should receive
energetic treatment.
The necessity for haste is evident. The toxin still free in the
blood must be neutralized as quickly as possible, and for this pur-
pose the intravenous injection of serum is advisable. Next in rapidity
of absorption is the intramuscular route, which should be employed
if for any reason the intravenous method cannot be used. Antitoxin
given subcutaneously reaches the maximum concentration in the blood
only toward the end of the second twenty-four-hour period after
TABLE 4
RESULTS WITH RESPECT TO TIME WHEN SERUM WAS GIVEN AND SIZE OF DOSE IN FIRST
TWENTy-FOUR HOURS OF TREATMENT*
Large Doses Small Doses Mortality
Incubation Died Recovered Died Recovered Large Dose 1 Small D.
A. Cases receiv ing first serum with in 24 hour of first symptoms:
10 days and less 41 13 21 3 75.9 87.5
Over 10 days .. 11 15 6 3 42.3 66.6
52 28 27
hou",;afte< I
65.0 81.8
B. Cases receiv ing first serum in second 24 first syrnp toms:
10 days and less 11 9 6 55.0 100.0
Over 10 days .. 2 8 1 20.0 ....
13 17 7 0 43.3 100.0
C. Cases receiv ing first serum over 48 hours after first symptoms:
10 days and less 10 6 7 4 62.5 63.6
Over 10 days .. 7 10 1 5 41.1 16.6
17 16 8 9 51.5 47.0
Grand Totals:
10 days and less 62 28 34 7 68.8 82.9
Over 10 days .. 20 33 8 8 37.7 50.0
82 61 42 15 57.3 73.7
* In this table a small dose = 3,000 units or less subcutaneously; a large dose = over
3,000 subcutaneously or 3,000 or less intraspinally or intravenously.
injection. This delay in absorption may entail a lapse of time suffi-
cient to allow the development of a fatal intoxication. It is true
that in some cases the formation of the toxin may proceed slowly,
so that the subcutaneous injection of antitoxin may prove life sav-
ing, but in the ordinary acute case a dose of 1,500 or 3,000 units given
subcutaneously can be of little immediate value in neutralizing toxin
in the blood and staying the course of the disease.
The importance of intraspinal injection of antitoxin as a means
of dealing with toxin that has already reached the central nervous
system has been recently emphasized by Park, who has shown that
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372 ERNEST E. IRONS
animals in which tetanus has already developed may be saved by
antitoxin in adequate doses and that the results are better and smaller
doses required when the antitoxin is given intraspinally than when
other routes are employed. These experimental results, together with
a number of favorable results in human tetanus, indicate that the
intraspinal injection of antitoxin should be urged in all cases of
tetanus.
The intraneural injection of antitoxin serves to neutralize that
portion of toxin peripheral to the point of injection in the nerves
supplying the infected extremity, but from what we know of the
distribution of toxin in the body in human tetanus, the instances in
which this method alone is life saving must be extremely rare.
In Table 4 the cases are divided into groups with respect to
( l.) the incubation period, (2) the time elapsing from the appearance
of symptoms to the beginning of treatment, and (3) the amount and
efficiency of method of inj ection of the antitoxin during the first
twenty-four hours of treatment. This classification may be criticised
as faulty in a number of particulars, but taking the cases in the
aggregate, it offers a basis of comparison as accurate as can be
obtained from the data available. A comparison of the mortalities
of cases receiving large and small doses of antitoxin shows the
importance of adequate dosage and proper method of injection. In
acute tetanus a small dose of antitoxin given subcutaneously does
very little good. The reduction of aggregate mortality over the mor-
tality of untreated tetanus is apparently due to the favorable results
obtained in the cases where larger doses were employed in an effi-
cient manner.
Some comment is necessary on the relative mortalities of cases
receiving large doses in the first and second twenty-four-hour periods.
The lower mortality in the second group (B) is obviously due not
to the postponement of treatment, but to the fact that a large number
of cases of acute tetanus die within twenty-four to thirty-six hours
after the appearance of symptoms. Such cases will necessarily appear
for the most part in the first group (A) and the second group (B)
will accordingly show a lower mortality, through this unavoidable
element of selection. Likewise the third group (C) contains some
cases with slower onset, milder course and correspondingly less grave
prognosis, in which necessity for rapid neutralization of toxin is
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TREATMENT OF TETANUS 373
less urgent, and the difference between the results obtained by 'large
and small doses of antitoxin disappears. It should be remembered,
however, that these cases are distinguishable only after the termina-
tion of illness, and the fact that they occur should be given no
weight in planning the treatment of the individual case. Every case
of tetanus is extremely serious.
Perhaps the most serious criticism to be urged against this classi-
fication of cases is that the grouping of cases as to duration of
symptoms prior to the giving of antitoxin into periods of twenty-
four hours, does not take into account whether patients received
TABLE 5
RESULTS WITH RESPECT TO TIME WHEN SERUM WAS GIVEN AND TOTAL AMOUNT*
OF SERUM USED
Large Doses Small Doses Mortality Percent
Incubation Died Recovered Died Recovered Large Dose Small D.
A. Cases receiv ing first serum with in 24 hours of first symptoms:
10 days and less 35 14 27 2 71.4 93.1
Over 10 days .. 10 16 7 2 41.5 77.7
45 30 34 4 60.0 89.4
B. Cases receiv ing first serum in second 24 hours after first symptoms:
10 days and less 11 9 6 0 55.0 100.0
Over 10 days .. 2 8 1 0 20.0 ~ ...
13 17 7 0 43.3 100.0
C. Cases receiv ing first serum over 48 hours after first symptoms:
10 days and less 6 7 11 3 46.1 78.5
Over 10 days .. 4 9 4 6 30.7 40.0
10 16 15 9 38.4 62.5
Grand Totals:
10 days and less 52 30 44 5 63.4 89.7
Over 10 days .. 16 33 12 8 32.6 60.0
68 63 56 13 51.9 81.1
* A small dose = 10,000 units or less subcutaneous. A large dose = over 10,000 sub-
cutaneous or less than 10,000 intraspinal or intravenous.
first treatment at the beginning or the end of the first twenty-four
hour period, i. e., whether antitoxin was administered immediately
after symptoms appeared or whether twenty-four hours elapsed before
treatment was begun. As pointed out by Park, twenty-four hours is
a long time in tetanus. The data available in the cases in this series
did not allow of a division of time smaller than twenty-four-hour
periods. With the more general appreciation of the necessity for
treatment immediately after the appearance of symptoms, more
accurate data, which should be stated in hours rather than days, will
be available for statistical study.
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374 ERNEST E. IRONS
In Table 5 the results of treatment with antitetanic serum are
tabulated with the same grouping as in Table 4, but with respect to
the total amount of serum used in each case. In this tabulation a
small dose is defined as 10,000 units or less, given subcutaneously,
and a large dose as more than 10,000 units subcutaneously or less than
10,000 units, if given intravenously or intraspinally. Most of the
cases receiving small doses were given 1,500 or 3,000 units per day,
subcutaneously, an amount obviously too small to be of service in
an acute case; while most of the cases in the class receiving large
doses were given considerably more than 10,000 units subcutaneously,
or less amounts intraspinally or intravenously. This purely arbitrary
division affords a basis for the comparison of the effects of dosage
in the series under discussion, but is not intended as a guide for the
treatment of the individual case. It should be noted that even in those
cases receiving relatively large doses subcutaneously, the distribu-
tion of dosage through the first twenty-four-hour period was such
that the maximum concentration of antitoxin could not have been
attained until well into the following twenty-four hours.
TABLE 6
MORTALITY OF TETANUS TREATED BY INTRASPINAL AND BY INTRAVENOUS INJECTIONS OF ANTI-
TOXIN, WITHOUT REGARD TO THE TIME TREATMENT WAS BEGUN
Cases
16
17
4
37
Intraspinal
Mortality,
Per Cent
81.2
29.4
56.7
Cases
11
5
4
20
Intravenous
Died
8
2
3
13
Mortality,
Per Cent
65.0
The method of grouping is subject to the same crrticisms as
that of Table 4, and in addition a further error is unavoidably intro-
duced in that those cases which died early in the disease had less
opportunity to receive large doses of antitoxin, and consequently
increase the percentage of mortality of the cases receiving small doses.
This accentuates unduly, the difference between results from large
and small doses.
In general the results with large doses are considerably better
than those with small doses, although as indicated above, the actual
difference is probably not as great as is indicated by the percentages.
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TREATMENT OF TETANUS 375
RESULTS WITH INTRAVENOUS AND INTRASPINAL INJECTIONS
A limited number of observations on the effects of intravenous and
intraspinal methods of injection are available in this series.
Twenty patients, of whom 11 were acute, 5 chronic, and 4
unknown incubation, received intravenous injections of serum either
alone or in combination with other methods of injection. The col-
lective mortality of these was 65 percent. Of those who died, how-
ever, treatment was begun within eight hours in 1, within twenty-four
hours in 5, on the third day in 2 and on the fourth day of symptoms,
or later, in 3. In 2 the duration of symptoms before treatment was
not noted.
Of 37 patients who received antitetanic serum intraspinally either
alone or in combination with other methods of injection, 16 were acute,
17 chronic and in 4 the incubation period was unknown. The col-
lective mortality was 56.7 percent. Of those who died 5 received
antitoxin within twenty-four hours after the appearanc= of symp-
toms, 5 received first treatment on the second day of symptoms, 4
on the third day, 2 on the fifth day or later, and in 3 the duration
of symptoms before treatment was not noted.
The delay of treatment until the second or third day of symp-
toms, and the small doses (1,500 to 3,000 units) which a number of
these patients received, go far toward explaining the failure of these
methods to reduce the death-rate in this series below 50 percent.
The unfortunate fact that often patients do not apply for treatment
until the second or even the third day of symptoms can not be used
as an argument against a method of treatment which offers a reason-
able hope of success if instituted early in the disease.
MAGNESIUM SULPHATE
Magnesium sulphate was given intraspinally in eighteen cases
which also received serum. Four cases, two acute and two chronic,
recovered, giving a mortality for the group of 77 percent. In two
cases death occurred shortly after the injection, with symptoms of
respiratory paralysis.
SUMMARY
From these statistics it appears that the mortality of tetanus
treated by tetanus antitoxin is about 20 percent lower than the average
mortality of tetanus treated without serum.
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376 ERNEST E. IRONS
The mortality of cases treated by efficient methods and adequate
dose is considerably lower than that of cases receiving small doses
subcutaneously.
SUGGESTIONS FOR THE TREATMENT OF TETANUS
The prophylactic value of tetanus antitoxin is established, and
needs no argument for its support. That tetanus antitoxin properly
used may save the life of a patient in whom tetanus has already
developed should be more generally recognized, and the treatment
employed in every case at the earliest moment possible. Every hour
lost before the giving of the antitoxin decreases the chance of saving
life. By no means every case will recover but certainly more can be
saved than have been in the past five years, and there is every reason
to anticipate that with a proper use of antitoxin a mortality consider-
ably lower than the present will be obtained.
It is important that the full effect of the antitoxin should be
obtained immediately and this may be accomplished by giving, as
outlined by Park, 3,000 to 5,000 units intraspinally and 10,000 to
20,000 units intravenously at the earliest possible moment after symp-
toms of tetanus appear. On the following day the intraspinal injec-
tion may be repeated. The blood remains strongly antitoxic for
several days. On the fourth or fifth day 10,000 units should be
given subcutaneously to maintain the antitoxin content of the blood.
It is doubtful whether the enormous doses given in some cases
over periods of many days are any more effective than the more
limited dosage outlined above by which the maximum concentration
of antitoxin in the .body is attained at once. If only a small amount
of antitoxin (3,000 to 5,000 units) is available it should be given
intraspinally. Intraspinal and intravenous injections should be given
with all the precautions usually employed for these methods.
The danger of immediate anaphylactic shock following intravenous
and intraspinal injection of tetanus antitoxin has been suggested as
an objection to these methods of giving the serum, but when we
consider the relative rarity of fatal instances of such complications
in the treatment of diphtheria either by intravenous or subcutaneous
injections, and the grave prognosis in untreated tetanus, it is evident
that the remote possibility of fatal serum disease should be given
little weight in determining treatment.
This use of antitoxin in no respect replaces other necessary recog-
nized non-specific methods of treatment in tetanus. Surgical treat-
 at U
niversity of Sussex on June 6, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
TREATMENT OF TETANUS 377
ment of the site of infection should be instituted at once. The
patient should be placed at rest in bed in a quiet darkened room, and
should receive sufficient sedatives to control convulsions, together
with adequate supply of fluid nourishment, and attention to the
elimination by kidney and bowel. The necessity for large and con-
tinued doses of sedatives such as chloral or chlorbutanol should not
blind the physician to the possible danger of giving an overdose. The
condition of the patient should be carefully watched, and a revision
of the standing orders for sedatives made whenever symptoms sug-
gest the decrease or increase of dose.
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